Abstract
Eli Lilly will release its quarterly results on April 30, 2026, Pre-Market, with investors watching how revenue and earnings progress against rapid growth in incretin-based therapies and new launches.Market Forecast
Consensus for the upcoming quarter points to revenue of 17.69 billion US dollars, up 39.65% year over year, and adjusted EPS of 6.63, up 119.15% year over year; EBIT is projected at 7.31 billion US dollars, up 106.16% year over year. There is no explicit gross margin or net profit margin forecast in the data set, but the projections imply a strong operating leverage profile.The company’s GLP‑1–anchored portfolio is expected to remain the principal revenue engine as supply expands and demand stays robust. The most promising growth vector is obesity therapeutics: Zepbound generated 4.26 billion US dollars last quarter, and management focus plus ongoing capacity additions suggest a supportive trajectory into this quarter.
Last Quarter Review
Eli Lilly delivered revenue of 19.29 billion US dollars last quarter (up 42.56% year over year), a gross profit margin of 82.52%, GAAP net profit attributable to shareholders of 6.64 billion US dollars with a net profit margin of 34.41%, and adjusted EPS of 7.54 (up 41.73% year over year).A key financial highlight was outperformance against street expectations: revenue of 19.29 billion US dollars exceeded the 17.96 billion US dollars consensus, and adjusted EPS of 7.54 topped the 6.67 consensus. Main-business momentum was concentrated in incretin therapies and oncology: tirzepatide (Mounjaro) contributed 7.41 billion US dollars, Zepbound contributed 4.26 billion US dollars, and Verzenio contributed 1.60 billion US dollars, underpinning the 42.56% year-over-year top-line growth.
Current Quarter Outlook (with major analytical insights)
Injectable GLP‑1 franchise momentum and earnings sensitivity
The upcoming print is highly sensitive to the performance of the injectable GLP‑1 franchise centered on tirzepatide across diabetes and obesity. The forecasted revenue of 17.69 billion US dollars and adjusted EPS of 6.63 imply that demand for Mounjaro and Zepbound continues to set the pace for top-line expansion, while fixed-cost absorption should support strong incremental margins. Prescription trends, fill rates, and inventory flow-through will matter because they translate directly into realized revenue and influence quarter-to-quarter variability more than list-price assumptions. Any evidence of sustained patient starts and persistence will be read as confirmation that the uptake remains broad-based, expanding beyond early-adopter channels.Operating leverage should be noticeable in the P&L even without explicit margin guidance, given the EBIT projection of 7.31 billion US dollars (up 106.16% year over year), which suggests a favorable gross-to-operating margin bridge if costs scale slower than revenue. Watch for incremental commentary on manufacturing throughput and distribution efficiency; improved throughput would help align realized sales with demand and limit backlogs. On the flip side, any hint of bottlenecks—whether in pen components, fill-finish capacity, or logistics—could defer portions of demand into subsequent quarters and constrain revenue recognition in the period.
Payer dynamics and patient affordability programs remain a tactical factor for realized net pricing and volume. While structural reimbursement trends are supportive, quarter-specific mix effects—such as copay support, channel inventory movements, and geographic shifts—can cause modest net price variability. The market’s 39.65% revenue growth expectation embeds robust volume assumptions; therefore, the risk-reward into the report hinges on whether volume delivery meets or exceeds those built-in expectations.
Obesity therapeutics and the oral incretin pathway
Obesity is the most watched growth vector in the near term. Zepbound’s 4.26 billion US dollars contribution last quarter illustrates the scale of demand for incretin-based weight management. For this quarter, the attention turns to sustainability of weekly prescription growth, adherence patterns, and refill rates, which together determine how quickly revenue compounds. Because Zepbound is still in the scale-up phase, supply cadence and channel inventory normalization can introduce timing noise in reported revenue; however, structural demand signals remain the key read-through for full-year trajectory.A second, complementary catalyst is the progress of the company’s oral GLP‑1 program Foundayo (orforglipron). Recently reported late-stage data showed clinically meaningful cardiovascular and metabolic outcomes alongside a safety profile consistent with prior evaluations, and management indicated plans to proceed with US regulatory submissions on that basis. While oral incretin revenue is not yet a driver in the current quarter, the path it opens—convenience, broader primary-care adoption, and potentially differentiated patient segments—shapes medium-term expectations and can influence sentiment immediately. Analysts will focus on management’s qualitative updates around launch readiness, manufacturing scale-up, and expected positioning relative to injectables.
In oncology, the portfolio continues to contribute diversification benefits. Verzenio’s 1.60 billion US dollars revenue last quarter reflects durable demand in its indications, and new combination data for Jaypirca in hematologic malignancies has reinforced asset optionality. These dynamics are not expected to overshadow incretins in the near term but can positively affect mix and margin quality as they compound steadily. For the quarter, incremental oncology updates are likely to be interpreted as supportive to longer-term revenue resilience.
Near-term stock price drivers around the print
Heading into the Pre-Market release on April 30, 2026, the stock’s response is likely to be most sensitive to three elements: realized incretin revenue versus implicit run-rate assumptions, clarity on manufacturing and supply ramp, and qualitative tone on oral incretin milestones and broader pipeline or business development. The top-line consensus at 17.69 billion US dollars already embeds strong growth, raising the bar for upside surprises. A beat on revenue accompanied by a clean operating expense trajectory would support the projected 106.16% year-over-year EBIT growth and likely sustain positive earnings revisions. Conversely, even a small shortfall tied to transitory supply gating could prompt near-term volatility given elevated expectations.Business development headlines have also shaped recent sentiment. The company announced an agreement to acquire CrossBridge Bio for up to 300 million US dollars, and market chatter has discussed a potential transaction for Kelonia Therapeutics. While not material to this quarter’s revenue, these moves frame a capital allocation stance that seeks to expand in oncology and next-generation cell therapy capabilities. Investors will parse management commentary for strategic fit, expected development timelines, and any near-term P&L implications such as in-process R&D charges or operating expense cadence.
Finally, the balance between volume growth and pricing dynamics will be read closely in the context of payer coverage, list-to-net evolution, and patient affordability programs. Clear messaging that net pricing remains stable while volumes scale would be taken as constructive for sustaining the implied 39.65% revenue growth and 119.15% EPS growth in the quarter. If management indicates that any mix shifts temporarily compress margins, investors may look past near-term noise so long as supply and prescription growth remain aligned with full-year targets.
Analyst Opinions
Recent research updates have been overwhelmingly favorable. Across the notable updates within the last six months, the balance of opinion has been decisively bullish, with the majority of institutions reiterating Buy or Overweight stances and raising or affirming ambitious price targets. The ratio of bullish to bearish views in the captured period is effectively unanimous in favor of bullish, underscoring conviction that growth in incretin therapies and pipeline catalysts can continue to translate into accelerating earnings.- UBS reiterated a Buy rating with a 1,250 US dollars price target, highlighting the company’s expansion into next‑generation in‑vivo cell therapy platforms as strategically additive to long-term optionality. The perspective links near-term commercial execution with longer-horizon innovation bets, reinforcing a multi-year growth narrative. - Scotiabank reaffirmed its Buy rating and set a 1,300 US dollars price target, emphasizing the continued scale of the incretin franchise and an expectation that demand will support sustained top-line and earnings expansion. Their stance implicitly assumes that supply ramp and channel inventory management will keep pace with broadening patient uptake. - Bernstein maintained a Buy rating with a 1,300 US dollars price target, reflecting confidence in the durability of prescription growth and improving operating leverage. The implied upside case leans on efficient cost scaling as revenue continues to compound, which aligns with the consensus projections for triple-digit EBIT growth this quarter. - J.P. Morgan reiterated a Buy rating and a 1,300 US dollars price target, citing robust demand signals and a supportive near-term catalyst path, including the company’s oral incretin program and oncology readouts. This view frames the quarter as an execution checkpoint rather than a make-or-break catalyst, with success measured by steady delivery against already strong baselines. - Wells Fargo maintained an Overweight/Buy rating with a 1,280 US dollars target, focusing on supply expansion updates and the incremental contribution of new therapies as key triggers for further estimate revisions. Their emphasis suggests that confirmation of supply cadence will be as important to the stock reaction as headline revenue and EPS numbers. - Guggenheim adjusted its target to 1,183 US dollars while maintaining a Buy rating, pointing to continued confidence in the core commercial engines and strategic pipeline developments. The tempered but constructive target recalibration acknowledges a high expectations bar while staying positive on fundamental drivers.
The majority view expects a solid print that validates demand durability, showcases progress on supply, and sets a constructive tone on the oral incretin trajectory. Analysts broadly argue that the combination of 39.65% revenue growth and 119.15% EPS growth forecast for this quarter demonstrates operating leverage from scale and a favorable product mix, even without explicit margin guidance. They also point to pipeline and business development as supportive to medium-term valuation, with CrossBridge and potential cell therapy assets bolstering diversification. The central risk noted within the bullish camp is not demand but rather execution sequencing—ensuring that manufacturing and distribution match prescription momentum to avoid pushing revenue recognition into future quarters. If management communicates tight alignment here and reiterates confidence in near-term capacity, the consensus expects the stock reaction to be constructive.
On balance, the institutional consensus into April 30, 2026 is bullish: revenue and earnings are expected to show strong year-over-year expansion, and the outlook commentary has the potential to sustain upward estimate revisions so long as the company demonstrates continued delivery on supply, launch execution, and pipeline milestones.
Comments